NeoPharm to Present at Merrill Lynch 2006 Global Pharmaceutical, Biotechnology & Medical Device Conference.WAUKEGAN, Ill. -- NeoPharm, Inc. (Nasdaq:NEOL) announced today that it has been invited to present at the Merrill Lynch Merrill Lynch & Co., Inc. (NYSE: MER TYO: 8675 ), through its subsidiaries and affiliates, provides capital markets services, investment banking and advisory services, wealth management, asset management, insurance, banking and related products and services on a global basis. 2006 Global Pharmaceutical, Biotechnology, & Medical Device Conference, scheduled for February 7-9, 2006 at the Grand Hyatt Hotel in New York City New York City: see New York, city. New York City City (pop., 2000: 8,008,278), southeastern New York, at the mouth of the Hudson River. The largest city in the U.S. . The NeoPharm presentation will be made by Guillermo A. Herrera, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. , on Thursday, February 9, 2006 from 1:40 p.m. - 2:10 p.m. Eastern Time. About NeoPharm, Inc. NeoPharm, Inc., based in Waukegan, Illinois Waukegan (IPA: /wɔˈkiːgən/) is a city in Lake County, Illinois. As of the 2000 census, the city had a total population of 87,901. Estimated population in 2006: 93,389 . , is a publicly traded biopharmaceutical company dedicated to the research, development and commercialization of new and innovative cancer drugs for therapeutic applications. The Company has a portfolio of cancer compounds in various stages of development. Additional information can be obtained by visiting NeoPharm's Website at www.neophrm.com. Forward Looking Statements - This press release contains "forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. " within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The Company has tried to identify such forward-looking statements by use of such words as "expects," "intends," "hopes," "anticipates," "believes," "could," "may," "evidences" and "estimates," and other similar expressions, but these words are not the exclusive means of identifying such statements. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc difficulties or delays in financing, development, testing, obtaining regulatory approval, production and marketing of the Company's drug and non-drug compounds, uncertainty regarding the availability of third party production capacity, unexpected adverse side effects Side effects Effects of a proposed project on other parts of the firm. or inadequate therapeutic efficacy of the Company's drug and non-drug compounds, that could slow or prevent products coming to market, uncertainty regarding the Company's ability to market its drug and non-drug products ,the uncertainty of patent protection for the Company's intellectual property or trade secrets, and other risks detailed from time to time in filings the Company makes with the Securities and Exchange Commission including its annual reports on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. and quarterly reports on Forms 10-Q. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, including those risks and uncertainties mentioned or referred to in this press release. Accordingly, you should not rely on these forward-looking statements as a prediction of actual future results. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion